Agios to Present Data From the Phase 3 ClarIDHy Study of TIBSOVO® in Previously Treated IDH1 Mutant Cholangiocarcinoma in Pr...
September 10 2019 - 7:00AM
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of
cellular metabolism to treat cancer and rare genetic diseases,
announces that results from the Phase 3 ClarIDHy study of TIBSOVO®
in previously treated IDH1 mutant cholangiocarcinoma have been
accepted for presentation in a Presidential Symposium at the
European Society for Medical Oncology (ESMO) Annual Meeting being
held September 27 – October 1, 2019 in Barcelona.
The schedule for the presentation by Agios is as follows:
Date & Time: Monday, September 30, 2019
from 4:30 p.m. – 4:42 p.m. CETTitle: ClarIDHy: A
global, phase 3, randomized, double-blind study of ivosidenib vs
placebo in patients with advanced cholangiocarcinoma with an
isocitrate dehydrogenase 1 (IDH1) mutationOral Abstract
Session: Presidential Symposium
IIIAbstract: LBA10Location:
Barcelona Auditorium (Hall 2)Presenter: Ghassan K.
Abou-Alfa, Memorial Sloan-Kettering Cancer Center
Conference Call InformationAgios will host a
conference call and live webcast with presentation slides on
September 30, 2019 at 1 p.m. ET /7 p.m. CET to discuss the data
from the ClarIDHy study. To participate in the conference call,
please dial 1-877-377-7098 (domestic) or 1-631-291-4547
(international) and refer to conference ID 5209309. The live
webcast can be accessed under “Events & Presentations” in the
Investors section of the company's website at www.agios.com. The
archived webcast will be available on the company's website
beginning approximately two hours after the event.
About Agios Agios is focused on discovering and
developing novel investigational medicines to treat cancer and rare
genetic diseases through scientific leadership in the field of
cellular metabolism and adjacent areas of biology. In addition to
an active research and discovery pipeline across both therapeutic
areas, Agios has two approved oncology precision medicines and
multiple first-in-class investigational therapies in clinical
and/or preclinical development. All Agios programs focus on
genetically identified patient populations, leveraging our
knowledge of metabolism, biology and genomics. For more
information, please visit the company's website
at www.agios.com.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include those
regarding the potential benefits of TIBSOVO® (ivosidenib); Agios’
plans regarding future data presentations; and the potential
benefit of its strategic plans and focus. The words “anticipate,”
“expect,” “intend,” “potential,” “milestone,” “goal,” “will,” “on
track,” “upcoming,” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Such
statements are subject to numerous important factors, risks and
uncertainties that may cause actual events or results to differ
materially from Agios' current expectations and beliefs. For
example, there can be no guarantee that any product candidate Agios
or its collaborators is developing will successfully commence or
complete necessary preclinical and clinical development phases, or
that development of any of Agios' product candidates will
successfully continue. Moreover, there can be no guarantee that the
two approved oncology precision medicines being commercialized by
Agios and its collaborators will receive commercial acceptance.
There can be no guarantee that any positive developments in Agios'
business will result in stock price appreciation. Management's
expectations and, therefore, any forward-looking statements in this
press release could also be affected by risks and uncertainties
relating to a number of other important factors, including: Agios'
results of clinical trials and preclinical studies, including
subsequent analysis of existing data and new data received from
ongoing and future studies; the content and timing of decisions
made by the U.S. FDA and other regulatory authorities,
investigational review boards at clinical trial sites and
publication review bodies; Agios' ability to obtain and maintain
requisite regulatory approvals and to enroll patients in its
planned clinical trials; unplanned cash requirements and
expenditures; competitive factors; Agios' ability to obtain,
maintain and enforce patent and other intellectual property
protection for any product candidates it is developing; Agios'
ability to maintain key collaborations; and general economic and
market conditions. These and other risks are described in greater
detail under the caption "Risk Factors" included in Agios’ public
filings with the Securities and Exchange Commission. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and Agios expressly disclaims any
obligation to update any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
required by law.
Investor & Media Contact: Holly Manning,
617-844-6630 Associate Director, Investor Relations
Holly.Manning@agios.com
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Sep 2023 to Sep 2024